Abstract P1-08-02: Breast tumor-specific MHC-II expression drives a unique pattern of adaptive resistance to antitumor immunity through MHC-II receptor checkpoint engagement

Justin M. Balko(Vanderbilt University Medical Center), R.E. Davis(University of Alabama), Roberto Salgado(Institut Jules Bordet), Violeta Sánchez(Vanderbilt University), MJ Nixon(University of Alabama), DM Shreeder(University of Alabama), JY Kim(University of Alabama), DL Rimm(University of Alabama), ME Sanders(University of Alabama), Jennifer Bordeaux(Lineage Cell Therapeutics (United States)), D.B. Johnson(University of Alabama), Sherene Loi(The University of Melbourne)
Cancer Research
February 15, 2018
10.1158/1538-7445.sabcs17-p1-08-02
Cited by 2

Related Papers

Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|The Lancet|2020|1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k